How fast is AI becoming part of diagnosis?

Faster than most healthcare technologies. The artificial intelligence in diagnostics market grew to USD 2.0 billion in 2025 and is estimated at USD 2.4 billion in 2026. By 2033 it is projected to reach USD 9.7 billion, expanding at a 21.7% CAGR from 2026 to 2033, per Grand View Research.

Who is capturing the most value today?

North America leads regionally with a 54.8% revenue share. Software is the top component at 46.2%. Neurology is the largest diagnosis type at 24.15%. The sections below break down what is driving these numbers, where the next wave of growth will come from, and which companies are shaping the market.

Market Size and Growth Forecasts

The artificial intelligence in diagnostics market is moving from pilot projects to routine clinical use. The jump from USD 2.0 billion to USD 2.4 billion between 2025 and 2026 is roughly 20% in a single year. Between 2026 and 2033, the market is projected to add about USD 7.3 billion in new revenue. By 2033 it would be nearly five times its 2025 size. These ratios are our own calculations from the report's figures, not numbers the report states.

The report attributes this growth to advances in machine learning and deep learning, which make diagnostic tools faster and more accurate. Its forecast covers 2026 to 2033, using 2025 as the base year.

Download a free sample report or claim your copy of this full market intelligence report

Leading Segments and Regions

By Component

Software led the artificial intelligence in diagnostics market with a 46.2% revenue share in 2025. It is also expected to grow at the fastest CAGR through the forecast period. Better algorithms and demand for real-time medical image analysis keep software ahead.

Hardware is expected to grow at a significant CAGR. In October 2025, Identifeye Health launched an AI-powered retinal camera that screens for diabetic retinopathy at the point of care, without needing a specialist on site.

By Diagnosis Type

Neurology held the largest share at 24.15% in 2025, driven by the burden of Alzheimer's and Parkinson's disease. A University of Nebraska Medical Center team built a dementia diagnostic model from the records of 51,269 participants across nine databases. The data combined exam findings, test results, and MRI scans.

Oncology is expected to grow at a significant CAGR as early cancer detection becomes a clinical priority. Ibex Medical Analytics, for example, refined its pathology AI for breast, prostate, and gastric tissue in September 2024.

By Region

North America dominated with a 54.8% revenue share in 2025, which works out to roughly USD 1.1 billion (our calculation). The U.S. was the largest national market. Government funding, such as the ARPA-H PRECISE-AI program, supports the region's lead.

• Europe: Significant CAGR, as overstretched health systems and workforce shortages push adoption. In the UK, Optellum secured joint NIHR and Office for Life Sciences funding under a USD 159.95 million (EUR 148 million) cancer initiative.
• Asia Pacific: Substantial CAGR. In India, the Punjab government deployed portable, radiation-free AI screening devices across eight districts, targeting 300 cancer and 600 eye screenings daily.
• Middle East & Africa: Strong growth. PureHealth opened a 70,000 sq ft AI-powered laboratory in Abu Dhabi that processes over 30 million samples a year.
• Latin America: Projected to grow at the fastest CAGR of any region.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Key Drivers and Challenges

What Is Pushing Growth

Disease burden is the main driver. NIH estimates from 2023 put about 2.0 million new cancer diagnoses in the U.S., including 297,790 breast cancer cases in women. The CDC reported 919,032 U.S. cardiovascular deaths in 2023, about one in every three deaths. Each case adds to the diagnostic workload, and AI helps providers absorb it.

• Cloud storage and computing now support AI-powered diagnostic systems.
• Shortages of healthcare workers make automation attractive.
• National programs such as India's Ayushman Bharat Digital Mission, Saudi Vision 2030, and UAE Vision 2031 fund digital health.
• The move to value-based care favors tools that catch disease early.

What Holds It Back

Regulation is the biggest constraint. The report rates its impact as high. The U.S. FDA applies its medical device framework through the AI/ML-Based SaMD Action Plan, and the UK's MHRA is running a 2025 change programme with regulatory sandboxes and NHS pilots.

Algorithm transparency is a second hurdle. Diagnostics.ai's CEO has described most diagnostic algorithms as opaque "black boxes." The company built its CE-IVDR-compliant PCR platform to make decisions traceable.

Data access is a third. GE HealthCare's chief science and technology officer noted that patient data is rarely accessible enough to inform diagnoses. Finally, regional expansion into emerging markets is still only moderate.

Key Market Players

The report describes the artificial intelligence in diagnostics market as consolidated, with high innovation and high M&A activity. Profiled companies include:

• Siemens Healthineers
• Zebra Technologies Corp.
• Riverain Technologies
• Vuno, Inc.
• Aidoc

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Their moves show the playbook. GE HealthCare acquired Intelligent Ultrasound's clinical AI software division for about USD 51 million in July 2024. Roche added over 20 AI algorithms from eight new partners to its digital pathology platform in September 2024. In November 2025, Philips extended its Cortechs.ai partnership to deliver zero-click quantitative brain reports inside its MR systems. Prenosis won the first FDA marketing authorization for an AI sepsis diagnostic in April 2024.

What the Numbers Suggest

Three patterns stand out in the artificial intelligence in diagnostics market.

1. Software is the profit pool. It holds the largest share and the fastest growth, so hardware vendors are bundling AI to stay relevant.
2. Partnerships beat solo builds. Nearly every milestone above is a collaboration or acquisition.
3. Regulatory readiness is a competitive edge. Companies that clear FDA and CE-IVDR pathways early, as Prenosis and Diagnostics.ai did, win trust faster.

Explore Our Dedicated Business Service – 

Grand View Signal – Commodity Pricing Intelligence - Grand View Signal is a pricing intelligence platform that delivers monthly price assessments, historical benchmarks, forward outlook and risk valuation. It turns complex pricing data into clear insights, helping leaders make better decisions and reduce risk through a simple three-stage workflow. 

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.